Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

Inclusion Criteria: * Patients must have a diagnosis of neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines * Patients must have high-risk neuroblastoma * Patients must have at least ONE of the following: * Recurrent/progressive disease at any time prior to enrollment - regardless of response to frontline therapy * Refractory disease: persistent sites of disease (after less than a partial response to frontline therapy, following a minimum of 4 cycles of induction therapy) AND patient has never had a relapse/progression * Persistent disease: persistent disease after achieving at least a partial response to frontline therapy after a minimum of 4 cycles of induction therapy and patient has never had a relapse/progression * Patients must have at least ONE of the following (lesions may have received prior radiation therapy as long as they meet the other criteria listed below): * Bone disease * At least one metaiodobenzylguanidine (MIBG) avid bone site or diffuse MIBG uptake * For recurrent/progressive or refractory disease a biopsy is not required regardless of number of MIBG avid lesions * For persistent disease, if patient has only 1 or 2 MIBG avid lesions OR a Curie score of 1-2, then biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one site present at the time of enrollment (bone marrow, bone, or soft tissue) is requ…